Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Haruo Sugiyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0844-2175; OpenAlex author ID A5021069937. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 17

  1. Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide… Last author DOI 10.1136/jitc-2024-011426↗
  2. Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable … Last author DOI 10.1136/jitc-2024-009765↗
  3. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08911-4↗
  4. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Res… Co-author DOI 10.21873/anticanres.14593↗
  5. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer. Co-author DOI 10.1080/07357907.2019.1661427↗
  6. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines. Co-author DOI 10.1080/21645515.2018.1524238↗
  7. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1. Co-author DOI 10.1159/000500359↗
  8. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Last author DOI 10.1158/2326-6066.cir-17-0386↗
  9. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Co-author DOI 10.21873/anticanres.12464↗
  10. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.8961↗
  11. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. Last author PMID 28950074↗
  12. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Last author DOI 10.2217/imt-2016-0031↗
  13. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for p… Co-author PMID 25550602↗
  14. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. Last author DOI 10.1097/cji.0000000000000020↗
  15. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0314↗
  16. Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. Co-author DOI 10.4161/21624011.2014.958950↗
  17. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Co-author DOI 10.1007/s00262-011-1033-3↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigeo Koido · 16 shared papers, 2011–2025 · strength 1.31
  2. Shigetaka Shimodaira · 8 shared papers, 2014–2025 · strength 0.81
  3. Zensho Ito · 7 shared papers, 2015–2025 · strength 0.76
  4. Masayuki Saruta · 6 shared papers, 2018–2025 · strength 0.72
  5. Masato Okamoto · 10 shared papers, 2014–2019 · strength 0.71
  6. Toshifumi Ohkusa · 4 shared papers, 2019–2025 · strength 0.57
  7. Shin Kan · 6 shared papers, 2014–2024 · strength 0.51
  8. Masamori Shimabuku · 2 shared papers, 2024–2025 · strength 0.38
  9. Shuichi Fujioka · 3 shared papers, 2018–2021 · strength 0.25
  10. Sadamu Homma · 6 shared papers, 2011–2018 · strength 0.22
  11. Mikio Kajihara · 4 shared papers, 2014–2019 · strength 0.21
  12. Kazuhiro Nagai · 2 shared papers, 2018–2020 · strength 0.21
  13. Shintaro Tsukinaga · 2 shared papers, 2014–2024 · strength 0.21
  14. Kazuki Takakura · 4 shared papers, 2014–2018 · strength 0.18
  15. Sumiyuki Nishida · 4 shared papers, 2011–2018 · strength 0.17
  16. Hisao Tajiri · 5 shared papers, 2011–2015 · strength 0.16
  17. Sayumi Yoshida · 2 shared papers, 2019 · strength 0.16
  18. Susumu Eguchi · 1 shared paper, 2020 · strength 0.13
  19. Yasushi Miyazaki · 1 shared paper, 2020 · strength 0.13
  20. Shuichi Hanada · 1 shared paper, 2019 · strength 0.11
  21. Sachie Kiryu · 1 shared paper, 2021 · strength 0.11
  22. Hidetoshi Eguchi · 2 shared papers, 2014–2018 · strength 0.09
  23. Hiroaki Nagano · 2 shared papers, 2014–2018 · strength 0.09
  24. Ryu Yanagisawa · 1 shared paper, 2018 · strength 0.08
  25. Tomoya Kanai · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.